Beckley Clinical, P.B.C.

### Executive Summary Beckley Clinical, P.B.C. (formerly NeuCo Holdings, P.B.C.), a Delaware corporation incorporated in 2023, has raised $7.4 million in a private placement under Regulation D, as reported in its initial Form D filing (SEC Accession No. 000213488726000001). The offering, which began on February 27, 2026, involves equity securities and includes six related persons—Joshua Stevens, Rock Feilding-Mellen, Daniel Love, Suprotik Basu, Michael Cotton, and Jennifer Hotes—who serve as executive officers and/or directors. The filing does not disclose the total offering amount, the number of investors, or whether non-accredited investors are participating, limiting the depth of analysis. This capital raise signals early-stage growth in the Other Health Care sector, with the company operating out of Nashua, New Hampshire. ### Investor Edge Watch for an amended Form D (D/A) that could reveal the total offering amount, investor count, and use of proceeds, which would provide clearer signals on the company's valuation and growth trajectory. Also, monitor the company's CIK record (0002134887) for any subsequent filings, such as a Form C or a future IPO registration, which would indicate a shift toward public markets. ### Sector capital positioning The $7.4 million raise in the Other Health Care sector reflects ongoing private capital flow into specialized health care ventures, particularly those with a public benefit corporation (P.B.C.) structure, which may attract impact-focused investors. Given the modest size and early stage (incorporated in 2023), this suggests a targeted, likely seed-to-Series A round, aligning with broader trends of increased private investment in niche health care innovations. ### Convergence Signals No direct convergence signals are evident from the filing alone. The company's name change from NeuCo Holdings to Beckley Clinical may indicate a strategic pivot or rebranding, but no associated patent filings, government contracts, or legislation are referenced. Investors should monitor the company's public filings and press releases for any clinical or regulatory milestones. ### Key Takeaways - Beckley Clinical raised $7.4M in a private equity placement under Regulation D, with first sale on 2026-02-27. - The company is a Delaware public benefit corporation incorporated in 2023, formerly named NeuCo Holdings. - Six related persons are listed as executive officers/directors, but no external investors or offering details are disclosed. ### Risk Indicators & Flags The filing lacks critical details such as the total offering amount, number of investors, and whether non-accredited investors are included, which may indicate a limited disclosure strategy. The company's short operating history (incorporated in 2023) and name change could signal operational or strategic risks. No sales commissions or use of proceeds to insiders are reported, but the absence of this data is not necessarily a red flag. ### Verification & References All data is directly from the SEC Form D filing (Accession No. 000213488726000001). The company's CIK (0002134887), entity name, address, previous name, incorporation year, and related persons are verifiable via SEC EDGAR. The capital raised ($7.4M) and first sale date (2026-02-27) are explicitly stated. The exemption rule (Regulation D) is inferred from the form type, but the specific sub-rule (506(b) or 506(c)) is not disclosed in the provided excerpt.